Sign in

You're signed outSign in or to get full access.

PC

PLEXUS CORP (PLXS)·Q3 2025 Earnings Summary

Executive Summary

  • Non-GAAP EPS of $1.90 beat guidance and Wall Street consensus, driven by strong gross margin execution, lower-than-anticipated interest expense and a favorable tax rate; GAAP diluted EPS was $1.64. Revenue was $1.018B, roughly in-line sequentially and with guidance, but modestly below S&P consensus; EBITDA was below consensus.*
  • Margin execution continued: GAAP operating margin rose to 5.3% and non-GAAP operating margin reached 6.0% near the high end of guidance; ROIC expanded to 14.1%, exceeding WACC by 520 bps.
  • Free cash flow was $13.2M; cash cycle increased to 69 days (+1 q/q) but inventory days improved by 4 days; sixth consecutive quarter of gross inventory reduction.
  • Q4 FY25 guidance implies sequential revenue growth ($1.025–$1.065B) and non-GAAP EPS of $1.82–$1.97; tax rate is guided down to 8–10% and capital spending for FY25 lowered as Malaysia site timing shifts to FY26—catalysts for estimate revisions and sentiment.

What Went Well and What Went Wrong

  • What Went Well

    • Margin execution and EPS beat: “Non-GAAP operating margin of 6.0% was near the high end of guidance and non-GAAP EPS of $1.90 exceeded guidance… free cash flow again surpassed our expectations.” — CEO Todd Kelsey.
    • ROIC strength: ROIC of 14.1% exceeded WACC by 520 bps; sustained working capital improvements, six consecutive quarters of gross inventory reduction.
    • Commercial momentum: 41 manufacturing program wins representing $250M annualized revenue; diversified across sectors; early signs of European defense sector activity.
  • What Went Wrong

    • Healthcare/Life Sciences grew 2% sequentially vs a mid-single-digit increase expected, due to a customer design update causing temporary production delay.
    • Semi cap program pushouts created timing friction (not perishable demand), contributing to EBITDA below consensus despite EPS beat.*
    • Cash cycle days rose to 69 (from 68), with a net $19M of advanced payments returned to customers; free cash flow, while positive, stepped down q/q.

Financial Results

MetricQ1 FY25 (Dec 28, 2024)Q2 FY25 (Mar 29, 2025)Q3 FY25 (Jun 28, 2025)
Revenue ($USD Billions)$0.976 $0.980 $1.018
Diluted EPS GAAP ($USD)$1.34 $1.41 $1.64
Adjusted EPS Non-GAAP ($USD)$1.73 $1.66 $1.90
Gross Margin (%)10.3% 10.0% 10.1%
Operating Margin GAAP (%)4.8% 5.0% 5.3%
ROIC (%)13.8% 13.7% 14.1%
Free Cash Flow ($USD Millions)$27.1 $16.5 $13.2

Segment breakdown by market sector ($USD Millions):

Market SectorQ1 FY25Q2 FY25Q3 FY25
Aerospace/Defense$160 (16%) $172 (18%) $183 (18%)
Healthcare/Life Sciences$374 (38%) $411 (42%) $420 (41%)
Industrial$442 (46%) $397 (40%) $415 (41%)
Total$976 $980 $1,018

Geographic segments ($USD Millions):

SegmentQ1 FY25Q2 FY25Q3 FY25
Americas$274 $295 $312
Asia-Pacific$607 $587 $594
Europe, Middle East & Africa$101 $103 $117
Inter-segment Eliminations$(6) $(5) $(5)
Total$976 $980 $1,018

KPIs and cash cycle components:

KPIQ1 FY25Q2 FY25Q3 FY25
Annualized Cash Cycle (days)68 68 69
Days in Accounts Receivable56 57 59
Days in Contract Assets12 12 13
Days in Inventory134 132 128
Days in Accounts Payable(69) (70) (72)
Days in Advanced Payments(65) (63) (59)
Program Wins (annualized rev)30; $212M 42; $205M 41; $250M
Top 10 Customers (% of revenue)51% 51% 48%
Share Repurchases ($USD Millions)$12.8 $12.2 $18.4

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($USD Billions)Q4 FY25$1.025–$1.065 Initiated
GAAP Diluted EPS ($USD)Q4 FY25$1.57–$1.72 Initiated
Non-GAAP EPS ($USD)Q4 FY25$1.82–$1.97 Initiated
Non-GAAP Operating Margin (%)Q4 FY255.7%–6.1% (framework) 5.7%–6.1% Maintained
Gross Margin (%)Q3 FY25 vs Q4 FY259.9%–10.2% (Q3 guide) 9.8%–10.1% (Q4 guide) Lowered
Selling & Administrative Expense ($M)Q3 vs Q4 FY25$50–$51 $50–$51 Maintained
Non-operating Expense ($M)Q3 vs Q4 FY25~$4.5 ~$4.5 Maintained
Effective Tax Rate (%)Q3 vs Q4 FY2514%–16% 8%–10% Lowered (reserve releases)
Diluted Shares (Millions)Q3 vs Q4 FY25~27.6 ~27.5 Lowered
Cash Cycle (days)Q3 vs Q4 FY2566–70 64–68 Improved
Capital Spending (FY25) ($M)FY25$110–$130 ~$80–$100 (shift to FY26) Lowered
Free Cash Flow (FY25) ($M)FY25Up to ~$100 ~100 Maintained

Note: No dividend guidance discussed.

Earnings Call Themes & Trends

TopicQ1 FY25 (Prior Two Quarters)Q2 FY25 (Prior Quarter)Q3 FY25 (Current)Trend
Semi cap demand and rampsExpect high-teens growth; share gains; stable overall WFE commentary Strong wins across top 5 customers; industrial ex-semi cap soft Pushouts “not perishable” demand; new program ramps buoy Q4 Mixed near-term; constructive FY26
Healthcare/Life SciencesDown in Q1; expecting ramps and recovery Up 10% q/q; improved outlook; large sustaining services win Up 2% q/q, below plan due to design update delay; wins $116M incl AFib platform rollout Recovery uneven; pipeline strong
Aerospace/DefenseWeak commercial aero; strong defense/space; conservative modeling Up high single digits; wins momentum; modest FY25 growth +6% q/q; early signs of European defense; flat Q4 outlook Defense tailwinds; commercial aero lag
Tariffs & tradeTariffs pass-through to customers; readiness to relocate In-region/for-region strategy; modeling scenarios Customers largely “wait and see”; USMCA compliance >80% in Mexico Ongoing uncertainty; minimal demand impact
Engineering Solutions2-year high in wins; leading indicator for manufacturing Best wins in 5+ years; diversification >$100M revenue; margin ~2x manufacturing; diversification across sectors Strategic differentiator, expanding
Malaysia capacity rampCapex elevated in FY25, new Penang site Site opening in summer; minimal margin drag expected Startup in Q4: “pretty minimal” drag; seeded with new business; quick to profitability Capacity added; quick ramp

Management Commentary

  • “Revenue of $1.018 billion met our guidance… Non-GAAP operating margin of 6% was near the high end of our guidance and non-GAAP EPS of $1.90 exceeded guidance.” — CEO Todd Kelsey.
  • “Non-GAAP EPS… exceeded our guidance due to… lower than anticipated interest expense and a favorable tax rate… we delivered $13,200,000 of free cash flow.” — CFO Patrick Jermain.
  • “We secured 41 new manufacturing programs with $250,000,000 in revenue annually when fully ramped… well-balanced across all market sectors.” — CEO Todd Kelsey.
  • “We are guiding revenue of $1.025 to $1.065 billion… At the midpoint… robust non-GAAP fiscal 2025 EPS growth of 26%.” — CEO Todd Kelsey.

Q&A Highlights

  • Semi cap pushouts are timing-related, not demand destruction; Q4 buoyed by new program ramps. “Moving revenue to the right… not perishable demand.” — COO Oliver Mihm.
  • Commercial aerospace remains muted; defense/space strong; European defense conversations increasing post Paris Air Show.
  • Malaysia site ramp: minimal margin drag in Q4; seeded with significant new business; expected quick path to profitability.
  • Capacity headroom: Utilization suggests >$5B revenue run-rate possible at full capacity; consistent across regions.
  • Tariffs: Costs passed to customers; limited demand shifts; USMCA compliance north of 80% in Mexico products.
  • Cash cycle target mid-to-low 60s achievable; continued focus on inventory and deposits.

Estimates Context

  • Q3 FY25 actuals vs S&P Global consensus:
    • Revenue: $1.0183B vs $1.0209B estimate* (slight miss).
    • Primary EPS: $1.90 vs $1.7117 estimate* (beat).
    • EBITDA: $73.334M vs $78.725M estimate* (miss).*
  • Q4 FY25 setup:
    • Company guidance: Revenue $1.025–$1.065B; non-GAAP EPS $1.82–$1.97; GAAP EPS $1.57–$1.72.
    • S&P Global consensus: Revenue $1.046B*; Primary EPS $1.863* (tax-rate guidance of 8–10% and lower interest expense may bias EPS estimates up).*

Values retrieved from S&P Global.*

Key Takeaways for Investors

  • EPS beat was quality-driven: gross margin strength, lower interest expense, and favorable tax rate; operating margin at 6% non-GAAP near high end provides confidence into Q4.
  • Revenue trajectory is sequentially positive across Q1–Q3 with diversified sector contributions; Healthcare/Life Sciences and Industrial both up q/q in Q3, albeit Healthcare below plan due to a customer design delay.
  • Working capital discipline remains central: inventory days improved, cash cycle guided to mid-60s; sustains ROIC well above WACC, supporting buybacks ($100M authorization).
  • Semi cap pushouts are timing-related; robust wins and ramps (Penang, Guadalajara) support FY26 growth across energy and semi cap.
  • European defense is an emerging growth lever; commercial aerospace recovery remains a future catalyst not embedded in FY26 outlook.
  • FY25 capital spending cut to ~$80–$100M with payments shifting to FY26; combined with ~$100M free cash flow and lower tax rate in Q4, estimates likely need upward EPS revision despite modest gross margin drag from Malaysia startup.
  • Near-term trading catalysts: non-GAAP EPS guidance implying ~26% FY25 growth, continued repurchases, and strong ROIC; watch Healthcare program ramp timing and tariff policy updates.

Other Relevant Q3 FY25 Materials

  • Fiscal 2024 Sustainability Report (June 2): Scope 1 & 2 emissions -6.4% YoY; waste-to-landfill intensity -13.7%; >20,000 paid volunteer hours; >50% of global supply chain spend assessed on sustainability criteria.